RxDoctor Payments Data

Mariana Chavez, MD

Surgical Oncology · Nashville, TNNPI 1265787550

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (50.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 87.2% of it on its own, with 16 other manufacturers making up the rest. Among surgical oncology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,930in general payments, 2019–2025

Across 74 payments — averaging $188.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$12K
  • Histosonics, Inc.$714
  • AbbVie$336
  • Smith+Nephew$145
  • Johnson & Johnson$133
  • W. L. Gore & Associates, Inc.$93
  • plus $355 from 11 others

What the payments were for

  • Travel & lodging$4,00629%
  • Food & beverage$2,91521%
  • Education$7,00050%
  • Gifts$90%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,930 in reported general payments places this provider in the 90th percentile of 53 surgical oncology providers in Tennessee.

See all surgical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$121,253
Medicare patients
170
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase27$30,129
Famotidine78$1,374
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$351
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$104
Tramadol Hcl53$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$336$30,12927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 53 surgical oncology providers in Tennessee.

Other surgical oncology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →